Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review

Atherosclerosis

Volumn 206, Issue 1, 2009, Pages 17-30

  Benn, Marianne ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Apolipoprotein B; Atherosclerosis; Epidemiology; Genetics; Ischemic heart disease; Ischemic stroke; Low density lipoprotein cholesterol

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR RISK; DNA POLYMORPHISM; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENE STRUCTURE; GENETIC CONSERVATION; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ALLELES; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; ISCHEMIA; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 67651041086     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.01.004     Document Type: Review

References (85)

1. Aguie G.A., Rader D.J., Clavey V., et al. Lipoproteins containing apolipoprotein B isolated from patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia: identification and characterization. Atherosclerosis 118 (1995) 183-191
2. Havel R.J., and Kane J.P. Structure and metabolism of plasma lipoproteins. In: Scriver C.R., Beaudet A.L., Valle D., et al. (Eds). The metabolic and molecular bases of inherited diseases. 8th ed. (2001), McGraw-Hill, New York 2705-2716
3. Brown M.S., and Goldstein J.L. Receptor-mediated endocytosis: insights from the lipoprotein receptor system. Proc Natl Acad Sci USA 76 (1979) 3330-3337
4. Havel R.J., and Kane J.P. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver C.R., Beaudet A.L., Valle D., et al. (Eds). The metabolic and molecular bases of inherited diseases. 8th ed. (2001), McGraw-Hill, New York 2717-2752
5. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
6. Tyroler H.A. Review of lipid-lowering clinical trials in relation to observational epidemiologic studies. Circulation 76 (1987) 515-522
7. Lamon-Fava S., Jimenez D., Christian J.C., et al. The NHLBI Twin Study: heritability of apolipoprotein A-I, B, and low density lipoprotein subclasses and concordance for lipoprotein(a). Atherosclerosis 91 (1991) 97-106
8. Heller D.A., de Faire U., Pedersen N.L., Dahlen G., and McClearn G.E. Genetic and environmental influences on serum lipid levels in twins. N Engl J Med 328 (1993) 1150-1156
9. Beekman M., Heijmans B.T., Martin N.G., et al. Heritabilities of apolipoprotein and lipid levels in three countries. Twin Res 5 (2002) 87-97
10. Vega G.L., and Grundy S.M. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest 78 (1986) 1410-1414
11. Tybjærg-Hansen A., Steffensen R., Meinertz H., Schnohr P., and Nordestgaard B.G. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 338 (1998) 1577-1584
12. Tybjærg-Hansen A., Jensen H.K., Benn M., et al. Phenotype of heterozygotes for low-density lipoprotein receptor mutations identified in different background populations. Arterioscler Thromb Vasc Biol 25 (2005) 211-215
13. Benn M., Nordestgaard B.G., Jensen J.S., et al. Mutation in apolipoprotein B associated with hypobetalipoproteinemia despite decreased binding to the low density lipoprotein receptor. J Biol Chem 280 (2005) 21052-21060
14. St-Pierre A.C., Cantin B., Dagenais G.R., Despres J.P., and Lamarche B. Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am J Cardiol 97 (2006) 997-1001
15. Talmud P.J., Hawe E., Miller G.J., and Humphries S.E. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 22 (2002) 1918-1923
16. Lamarche B., Moorjani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 94 (1996) 273-278
17. Chien K.L., Hsu H.C., Su T.C., et al. Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J Lipid Res 48 (2007) 2499-2505
18. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298 (2007) 776-785
19. McQueen M.J., Hawken S., Wang X., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372 (2008) 224-233
20. Elovson J., Chatterton J.E., Bell G.T., et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 29 (1988) 1461-1473
21. Jiang R., Schulze M.B., Li T., et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 27 (2004) 1991-1997
22. Ridker P.M., Rifai N., Cook N.R., Bradwin G., and Buring J.E. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294 (2005) 326-333
23. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
24. Moss A.J., Goldstein R.E., Marder V.J., et al. Thrombogenic factors and recurrent coronary events. Circulation 99 (1999) 2517-2522
25. Walldius G., Aastveit A.H., and Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 259 (2006) 259-266
26. Chien K.L., Sung F.C., Hsu H.C., et al. Apolipoprotein A-I and B and stroke events in a community-based cohort in Taiwan: report of the Chin-Shan Community Cardiovascular Study. Stroke 33 (2002) 39-44
27. Koren-Morag N., Goldbourt U., Graff E., and Tanne D. Apolipoproteins B and AI and the risk of ischemic cerebrovascular events in patients with pre-existing atherothrombotic disease. J Neurol Sci (2008)
28. Benn M., Nordestgaard B.G., Jensen G.B., and Tybjærg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B. The Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 27 (2007) 661-670
29. Pischon T., Girman C.J., Sacks F.M., et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 (2005) 3375-3383
30. Wilson P.W.F., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
31. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143.
32. Grundy S.M., Cleeman J.I., Merz C.N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
33. Pyörälä K., Debacker G., Graham I., Poolewilson P., and Wood D. Prevention of coronary heart-disease in clinical-practice-recommendations of the task-force of the European-Society of Cardiology, European Atherosclerosis Society and European-Society of Hypertension. Eur Heart J 15 (1994) 1300-1331
34. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51 (2008) 1512-1524
35. Knott T.J., Pease R.J., Powell L.M., et al. Complete protein-sequence and identification of structural domains of human apolipoprotein-B. Nature 323 (1986) 734-738
36. Cladaras C., Hadzopoulou-Cladaras M., Nolte R.T., Atkinson D., and Zannis V.I. The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms. EMBO J 5 (1986) 3495-3507
37. Chen S.H., Yang C.Y., Chen P.F., et al. The complete cDNA and amino acid sequence of human apolipoprotein B-100. J Biol Chem 261 (1986) 12918-12921
38. Law S.W., Grant S.M., Higuchi K., et al. Human liver apolipoprotein B-100 cDNA: complete nucleic acid and derived amino acid sequence. Proc Natl Acad Sci USA 83 (1986) 8142-8146
39. Zerba K.E., Kessling A.M., Davignon J., and Sing C.F. Genetic structure and the search for genotype-phenotype relationships: an example from disequilibrium in the Apo B gene region. Genetics 129 (1991) 525-533
40. Jenner K., Sidoli A., Ball M., et al. Characterization of genetic markers in the 3′ end of the apo B gene and their use in family and population studies. Atherosclerosis 69 (1988) 39-49
41. Benn M., Stene M.C., Nordestgaard B.G., et al. Common and rare alleles in apolipoprotein B contribute to plasma levels of LDL cholesterol in the general population. J Clin Endocrinol Metab (2007)
42. Chiodini B.D., Barlera S., Franzosi M.G., et al. APO B gene polymorphisms and coronary artery disease: a meta-analysis. Atherosclerosis 167 (2003) 355-366
43. Boekholdt S.M., Peters R.J.G., Fountoulaki K., Kastelein J.J.P., and Sijbrands E.J.G. Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis. Hum Genet 113 (2003) 417-425
44. Mann C.J., Anderson T.A., Read J., et al. The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins. J Mol Biol 285 (1999) 391-408
45. Bradbury P., Mann C.J., Kochl S., et al. A common binding site on the microsomal triglyceride transfer protein for apolipoprotein B and protein disulfide isomerase. J Biol Chem 274 (1999) 3159-3164
46. Segrest J.P., Jones M.K., De Loof H., and Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 42 (2001) 1346-1367
47. Chatterton J.E., Phillips M.L., Curtiss L.K., et al. Immunoelectron microscopy of low-density lipoproteins yields A Ribbon and Bow Model for the conformation of apolipoprotein-B on the lipoprotein surface. J Lipid Res 36 (1995) 2027-2037
48. Borén J., Lee I., Zhu W., et al. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J Clin Invest 101 (1998) 1084-1093
49. Benn M., Nordestgaard B.G., Jensen J.S., et al. Polymorphism in APOB associated with increased low-density lipoprotein levels in both genders in the general population. J Clin Endocrinol Metab 90 (2005) 5797-5803
50. Soria L.F., Ludwig E.H., Clarke H.R.G., et al. Association between a specific apolipoprotein-B mutation and familial defective apolipoprotein-B-100. Proc Natl Acad Sci USA 86 (1989) 587-591
51. Ludwig E.H., Hopkins P.N., Allen A., et al. Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins. J Lipid Res 38 (1997) 1361-1373
52. Parhofer K.G., Barrett P.H.R., Bier D.M., and Schonfeld G. Lipoproteins containing the truncated apolipoprotein, Apo B-89, are cleared from human plasma more rapidly than Apo B-100 containing lipoproteins in vivo. J Clin Invest 89 (1992) 1931-1937
53. Gaffney D., Reid J.M., Cameron I.M., et al. Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. Arterioscler Thromb Vasc Biol 15 (1995) 1025-1029
54. Pullinger C.R., Hennessy L.K., Chatterton J.E., et al. Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest 95 (1995) 1225-1234
55. Borén J., Ekstrom U., Agren B., Nilsson-Ehle P., and Innerarity T.L. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem 276 (2001) 9214-9218
56. Tybjærg-Hansen A., Gallagher J., Vincent J., et al. Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis 80 (1990) 235-242
57. Pietzsch J., Wiedemann B., JuLius U., et al. Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach. J Lipid Res 37 (1996) 2074-2087
58. Gaffney D., Forster L., Caslake M.J., et al. Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia. Atherosclerosis 162 (2002) 33-43
59. Innerarity T.L., Weisgraber K.H., Arnold K.S., et al. Familial defective apolipoprotein B-100-low-density lipoproteins with abnormal receptor-binding. Proc Natl Acad Sci USA 84 (1987) 6919-6923
60. Pullinger C.R., Gaffney D., Gutierrez M.M., et al. The apolipoprotein B R3531C mutation. Characteristics of 24 subjects from 9 kindreds. J Lipid Res 40 (1999) 318-327
61. Nissen H., Hansen P.S., Faergeman O., and Horder M. Mutation screening of the codon 3500 region of the apolipoprotein B gene by denaturing gradient-gel electrophoresis. Clin Chem 41 (1995) 419-423
62. Gaffney D., Pullinger C.R., O'Reilly D.S., et al. Influence of an asparagine to lysine mutation at amino acid 3516 of apolipoprotein B on low-density lipoprotein receptor binding. Clin Chim Acta 321 (2002) 113-121
63. Korhonen T., Savolainen M.J., and Kesaniemi Y.A. Variation of apolipoprotein B as a possible cause of decreased low density lipoprotein clearance and hypercholesterolemia. Atherosclerosis 146 (1999) 1-10
64. Series J., Cameron I., Caslake M., et al. The Xba1 polymorphism of the apolipoprotein B gene influences the degradation of low density lipoprotein in vitro. Biochim Biophys Acta 1003 (1989) 183-188
65. Demant T., Houlston R.S., Caslake M.J., et al. Catabolic rate of low density lipoprotein is influenced by variation in the apolipoprotein B gene. J Clin Invest 82 (1988) 797-802
66. Houlston R.S., Turner P.R., Revill J., Lewis B., and Humphries S.E. The fractional catabolic rate of low density lipoprotein in normal individuals is influenced by variation in the apolipoprotein B gene: a preliminary study. Atherosclerosis 71 (1988) 81-85
67. Benn M., Nordestgaard B.G., Jensen J.S., and Tybjærg-Hansen A. Polymorphisms in apolipoprotein B and risk of ischemic stroke. J Clin Endocrinol Metab 92 (2007) 3611-3617
68. Kruglyak L., and Nickerson D.A. Variation is the spice of life. Nat Genet 27 (2001) 234-236
69. Sunyaev S., Ramensky V., Koch I., et al. Prediction of deleterious human alleles. Hum Mol Genet 10 (2001) 591-597
70. Margulies E.H., Chen C.W., and Green E.D. Differences between pair-wise and multi-sequence alignment methods affect vertebrate genome comparisons. Trends Genet 22 (2006) 187-193
71. Ng P.C., and Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31 (2003) 3812-3814
72. Thomas P.D., Kejariwal A., Campbell M.J., et al. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 31 (2003) 334-341
73. Kotowski I.K., Pertsemlidis A., Luke A., et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 78 (2006) 410-422
74. Fouchier S.W., Defesche J.C., Kastelein J.J., and Sijbrands E.J. Familial defective apolipoprotein B versus familial hypercholesterolemia: an assessment of risk. Semin Vasc Med 4 (2004) 259-264
75. Humphries S.E., Whittall R.A., Hubbart C.S., et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 43 (2006) 943-949
76. Linsel-Nitschke P., Götz A., Erdmann J., et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease-a Mendelian Randomisation Study. PLoS ONE 3 (2008) e2986
77. Cohen J., Pertsemlidis A., Kotowski I.K., et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37 (2005) 161-165
78. Lander E.S. The new genomics: global views of biology. Science 274 (1996) 536-539
79. Chakravarti A. Population genetics-making sense out of sequence. Nat Genet 21 (1999) 56-60
80. Lohmueller K.E., Pearce C.L., Pike M., Lander E.S., and Hirschhorn J.N. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 33 (2003) 177-182
81. Pritchard J.K. Are rare variants responsible for susceptibility to complex diseases?. Am J Hum Genet 69 (2001) 124-137
82. Pritchard J.K., and Cox N.J. The allelic architecture of human disease genes: common disease-common variant ... or not?. Hum Mol Genet 11 (2002) 2417-2423
83. Cohen J.C., Kiss R.S., Pertsemlidis A., et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305 (2004) 869-872
84. Frikke-Schmidt R., Nordestgaard B.G., Jensen G.B., and Tybjærg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 114 (2004) 1343-1353
85. Kathiresan S., Melander O., Anevski D., et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358 (2008) 1240-1249